Biopharmaceutical company Amarin Corp Plc said it raised $100 million in non-equity financing that will help it form a sales force to launch its heart drug Vascepa, but disappointed investors hoping for a sale or partnership.
An experimental drug improved walking ability in boys suffering from a rare degenerative disease that causes progressive muscle loss, data from a new study showed, nearly tripling the market value of its developer Sarepta Therapeutics Inc.
Alexza Pharmaceuticals Inc resubmitted the marketing application for its anti-agitation treatment earlier than expected, sending its shares up as much as 47 percent.
Nektar Therapeutics said it agreed to sell its future royalties on two drugs to Royalty Pharma for $124 million, to help repay debt.
Life Technologies said it started taking orders for its "$1000 genome" device, placing the maker of life sciences tools in pole position in an industry-wide race to build the cheapest and fastest platform for gene sequencing.